Exosomes as a novel nanomedicine platform for personalized triple-negative breast cancer therapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Sun D, Zhuang X, Zhang S et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv. Drug Deliv. Rev. 65(3), 342–347 (2013).
  Medline CASGoogle Scholar
• 2. Tang W, Xia M, Liao Y, Fang Y, Wen G, Zhong J. Exosomes in triple negative breast cancer: from bench to bedside. Cancer Lett. 527, 1–9 (2022). • Describes the roles of exosomes in triple-negative breast cancer.
  Medline CASGoogle Scholar
• 3. Muthu MS, Agrawal P, Singh S. Theranostic nanomedicine of gold nanoclusters: an emerging platform for cancer diagnosis and therapy. Nanomedicine (Lond.) 11(4), 327–330 (2016).
  CASGoogle Scholar
• 4. Banerjee M, Rajeswari VD. Critical review on the different roles of exosomes in TNBC and exosomal-mediated delivery of microRNA/siRNA/lncRNA and drug targeting signalling pathways in triple-negative breast cancer. Molecules 28(4), 1–20 (2023). •• Complies with exosomal-mediated therapeutics delivery to triple-negative breast cancer.
  Google Scholar
• 5. Mehata AK, Viswanadh MK, Priya V, Muthu MS. Dendritic cell-targeted theranostic nanomedicine: advanced cancer nanotechnology for diagnosis and therapy. Nanomedicine (Lond.) 15(10), 947–949 (2020).
  CASGoogle Scholar
• 6. Akhmetov I, Bubnov RV. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J. 6, 1–12 (2015).
  MedlineGoogle Scholar
• 7. Murar M, Albertazzi L, Pujals S. Advanced optical imaging-guided nanotheranostics towards personalized cancer drug delivery. Nanomaterials (Basel) 12(3), 1–17 (2022).
  Google Scholar
• 8. Weaver JW, Zhang J, Rojas J, Musich PR, Yao Z, Jiang Y. The application of exosomes in the treatment of triple-negative breast cancer. Front. Mol. Biosci. 9, 1022725 (2022).
  Medline CASGoogle Scholar
• 9. Cully M. Exosome-based candidates move into the clinic. Nat. Rev. Drug Discov. 20(1), 6–7 (2021).
  Medline CASGoogle Scholar
• 10. Gong C, Tian J, Wang Z et al. Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. J. Nanobiotechnol. 17(1), 93 (2019).
  MedlineGoogle Scholar
• 11. Yu M, Gai C, Li Z et al. Targeted exosome-encapsulated erastin-induced ferroptosis in triple-negative breast cancer cells. Cancer Sci. 110(10), 3173–3182 (2019). •• Presents iron-assisted apoptosis promoted in triple-negative breast cancer via exosomal delivery of erastin.
  Medline CASGoogle Scholar
• 12. Piffoux M, Silva AKA, Wilhelm C, Gazeau F, Tareste D. Modification of extracellular vesicles by fusion with liposomes for the design of personalized biogenic drug delivery systems. ACS Nano 12(7), 6830–6842 (2018).
  Medline CASGoogle Scholar
• 13. Delong RK, Risor A, Kanomata M et al. Characterization of biomolecular nanoconjugates by high-throughput delivery and spectroscopic difference. Nanomedicine (Lond.) 7(12), 1851–1862 (2012).
  CASGoogle Scholar
• 14. Mullis AS, Jacobson SJ, Narasimhan B. High-throughput synthesis and screening of rapidly degrading polyanhydride nanoparticles. ACS Comb. Sci. 22(4), 172–183 (2020).
  Medline CASGoogle Scholar
• 15. Adir O, Poley M, Chen G et al. Integrating artificial intelligence and nanotechnology for precision cancer medicine. Adv. Mater. 32(13), e1901989 (2020).
  Medline CASGoogle Scholar
• 16. Dahlman JE, Kauffman KJ, Xing Y et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl Acad. Sci. USA 114(8), 2060–2065 (2017).
  Medline CASGoogle Scholar
• 17. Majumder B, Baraneedharan U, Thiyagarajan S et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat. Commun. 6, 6169 (2015).
  Medline CASGoogle Scholar
• 18. Apaya MK, Shiau JY, Liao GS et al. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple-negative breast cancer. J. Exp. Clin. Cancer Res. 38(1), 187 (2019).
  MedlineGoogle Scholar
• 19. Rosenblum D, Peer D. Omics-based nanomedicine: the future of personalized oncology. Cancer Lett. 352(1), 126–136 (2014).
  Medline CASGoogle Scholar
• 20. Liu X, Tang I, Wainberg ZA, Meng H. Safety considerations of cancer nanomedicine–a key step toward translation. Small 16(36), e2000673 (2020). • Demonstrates the safety margin of nanomedicines for clinical translation.
  Medline CASGoogle Scholar